Umar Syed most recently was the Senior Vice President of Corporate Development at MedReleaf. Mr. Syed has over 27 years of experience in the healthcare and pharmaceutical industry and notably was a co-founder and executive leader of the first North American publicly traded cannabis R&D product development company, Cannasat Therapeutics Inc, in 2004. Cannasat was later named Cynapsus Therapeutics and was sold for $820M CAD to Sunovion Pharmaceuticals Inc. of Japan in 2016. Prior to joining MedReleaf, Mr. Syed was Vice President of Global Strategy and Portfolio Management at Pharmascience Inc., among Canada's largest pharmaceutical companies with distribution in over 60 countries.
Mr. Syed began his career as a clinical pharmacist, and his experience includes senior pharmaceutical corporate development and strategic advisory roles. His experience ranges from building drug product portfolios through internal R&D or through acquisition/partnerships to planning and international commercialization organically and through M&A. His previous experience also includes strategic consulting for the Pharmaceutical and Healthcare Practice at The McKenna Group and later for Oliver Wyman in New York, as well as a Biotechnology and Pharmaceuticals Equity Research Analyst at BMO Nesbitt Burns.
Mark was an early investor in Canadian technology success stories such as Eicon Technologies, MVS ModularVision Systems, and Gage Applied Sciences. Mark’s core areas of expertise are finance, business development, product management, and strategic planning.
Mark entered the CBD industry to help identify and leverage multiple business opportunities, and he is directing his expertise in these areas to propel CBD into the mainstream of pain and inflammation management. Mark is a Harvard Business School graduate and has been starting, building and selling technology companies for over 30 years.